Massimo Giachetti/iStock Editorial via Getty Images
- EOM Pharmaceuticals (OTCPK:IMUC) has filed to uplist from the Pink Sheets to the Nasdaq.
- As part of the application, EOM would trade on the Nasdaq under the ticker "EOM."
- EOM (formerly ImmunoCellular Therapeutics) has two candidates in the clinical stage, EOM613 and EOM147. The former is in phase 2 for cancer cachexia, HIV/AIDS, and rheumatoid arthritis. EOM 147 is in phase 2 for age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vein occlusion.